NCT02474576

Brief Summary

The efficiency of percutaneous aponeurotomy in the treatment of Dupuytrens disease is well known. However, the duration of the clinical improvement after aponeurotomy is not well known. This study aims primarily at measuring the incidence rate of local relapse of Dupuytrens-induced finger flessum, within two years following treatment by percutaneous aponeurotomy in Dupuytrens.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
130

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 17, 2015

Completed
3 months until next milestone

Study Start

First participant enrolled

September 1, 2015

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2020

Completed
Last Updated

February 11, 2021

Status Verified

February 1, 2021

Enrollment Period

3.6 years

First QC Date

June 12, 2015

Last Update Submit

February 10, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Frequency of local relapse at 24 months

    the statistical unit is the finger treated by aponeurotomy (we expect an average of 2 fingers treated for one patient included). Local relapse is defined as the recurrence of a finger flessum superior by 20° to the articular range initially obtained after aponeurotomy

    24 months after treatment by aponeurotomy

Secondary Outcomes (5)

  • Primary success rate of aponeurotomy

    3 months after treatment

  • Frequency of local relapse at 12 months

    12 months after treatment by aponeurotomy

  • Frequency of local relapse at 36 months

    36 months after treatment by aponeurotomy

  • Frequency of local relapse at 48 months

    48 months after treatment by aponeurotomy

  • Frequency of local relapse at 60 months

    60 months after treatment by aponeurotomy

Study Arms (1)

Percutaneous aponeurotomy

EXPERIMENTAL

Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy

Procedure: Percutaneous aponeurotomy

Interventions

The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.

Percutaneous aponeurotomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient suffers from Dupuytren disease
  • Patient has at least one finger with at least 20° flessum on the metacarpophalangeal joint and/or on the proximal interphalangeal joint
  • Patient has chosen to benefit from local treatment

You may not qualify if:

  • Pregnancy
  • Breastfeeding
  • No social insurance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diaconesses Croix Saint-Simon Hospital Group

Paris, 75020, France

Location

MeSH Terms

Conditions

Dupuytren Contracture

Condition Hierarchy (Ancestors)

FibromaNeoplasms, Fibrous TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsContractureMuscular DiseasesMusculoskeletal DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2015

First Posted

June 17, 2015

Study Start

September 1, 2015

Primary Completion

April 1, 2019

Study Completion

April 1, 2020

Last Updated

February 11, 2021

Record last verified: 2021-02

Locations